Filtered By:
Source: Thrombosis Research
Condition: Thrombosis
Drug: Warfarin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 31 results found since Jan 2013.
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
Abstract: Background: Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done mostly in Western countries. It remains to be seen whether dabigatran will be cost effective in a practice environment where warfarin is significantly underused and the costs of both warfarin and international normalized ration INR monitoring are cheap.Methods: We performed a cost-effectiveness analysis with a Markov model to evaluate the value of dabigatran to prevent stroke and systemic embolism in patients with atrial fibrillation (AF) in Taiwan. Dabigatran was given through sequential dosing, where patients
Source: Thrombosis Research - March 17, 2014 Category: Hematology Authors: Chia-Hsien Chang, Yea-Huei Kao Yang, Jyh-Hong Chen, Li-Jen Lin Tags: Clinical Studies Source Type: research
Anticoagulation for stroke prevention in new atrial fibrillation after coronary artery bypass graft surgery
The benefit of early anticoagulation for stroke prophylaxis in atrial fibrillation after coronary artery bypass graft (CABG) surgery is uncertain. We therefore studied what proportion of ischemic strokes in patients with atrial fibrillation early after CABG surgery were potentially preventable by anticoagulation with warfarin.
Source: Thrombosis Research - February 24, 2015 Category: Hematology Authors: S. Schulman, I. Cybulsky, J. Delaney Tags: Regular Article Source Type: research
Warfarin non-persistence among stroke patients with atrial fibrillation
Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). For AF patients with stroke a warfarin persistence rate of 0.45 after 2years has previously been reported. No consistent predictors for discontinuation have been established.
Source: Thrombosis Research - July 30, 2015 Category: Hematology Authors: Fredrik Björck, Henrik Renlund, Peter J. Svensson, Anders Själander Tags: Full length article Source Type: research
Warfarin persistence among stroke patients with atrial fibrillation
Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). For AF patients with stroke a warfarin persistence rate of 0.45 after 2years has previously been reported. No consistent predictors for discontinuation have been established.
Source: Thrombosis Research - July 30, 2015 Category: Hematology Authors: Fredrik Björck, Henrik Renlund, Peter J. Svensson, Anders Själander Tags: Full Length Article Source Type: research
Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand
Novel oral anticoagulants (NOACs) and warfarin care bundles (e.g. genotyping, patient self-testing or self-management) are alternatives to usual warfarin care for stroke prevention in patients with atrial fibrillation (AF). We aim to evaluate the cost-effectiveness of NOACs and warfarin care bundles in patients with AF in a middle-income country, Thailand.
Source: Thrombosis Research - November 14, 2019 Category: Hematology Authors: Siok Shen Ng, Surakit Nathisuwan, Arintaya Phrommintikul, Nathorn Chaiyakunapruk Tags: Full Length Article Source Type: research
Comparing patient-level and site-level anticoagulation control as predictors of adverse events
Conclusion: iTTR significantly predicted risk of major hemorrhage, ischemic stroke, and all-cause mortality. cTTR was a weak predictor of all-cause mortality. Though cTTR may be a better target for site-level quality improvement efforts, iTTR may be a more suitable measure for use in comparative effectiveness research.
Source: Thrombosis Research - February 6, 2014 Category: Hematology Authors: Ramon S. Cancino, Elaine M. Hylek, Joel I. Reisman, Adam J. Rose Tags: Coagulation and Fibrinolysis Source Type: research
Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion
Conclusion: We found a low risk for stroke in the absence of postoperative bridging. For patients with device replacement surgery reversal of the anticoagulant effect at the time of procedure might reduce the risk for pocket hematoma, but this requires prospective evaluation including the risk of thromboembolism.
Source: Thrombosis Research - January 31, 2013 Category: Hematology Authors: S. Schulman, J. Schoenberg, S. Divakara Menon, A.C. Spyropoulos, J.S. Healey, J.W. Eikelboom Tags: Clinical Studies Source Type: research
Ensuring medication adherence with direct oral anticoagulant drugs: Lessons from adherence with vitamin K antagonists (VKAs)
Abstract: Medication adherence (taking drugs properly) is uncommon among patients on warfarin. Poor adherence to warfarin leads to an increase in adverse medical events, including stroke in atrial fibrillation (AF). Factors related to patients, physicians and the health system account for poor adherence. Direct oral anticoagulants (DOACs) are easier to use than warfarin, with fewer drug and food interactions and no need for routine blood monitoring. A proper use of DOACs may reduce the risk of stroke in AF. However, in clinical settings where no laboratory monitoring is needed, a poor medication adherence is common and may...
Source: Thrombosis Research - February 12, 2014 Category: Hematology Authors: Alessandro Di Minno, Gaia Spadarella, Antonella Tufano, Domenico Prisco, Giovanni Di Minno Tags: Mini-Reviews Source Type: research
Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system
Atrial fibrillation (AF) is most frequent arrhythmia in patients with chronic kidney disease (CKD) [1,2]. Since diabetes and hypertension are risk components of CHADS2 score and also risk factors for CKD, CKD could affect cardiovascular outcomes in patients with AF [2–5]. Indeed, several papers have shown that renal dysfunction increases the risk of thromboembolic events, stroke and all-cause mortality in AF patients [2–5]. In randomized trials of AF patients with stage III CKD, novel oral anticoagulant, dabigatran 150mg twice daily was superior to warfarin for stroke prevention, while apixaban was superior in regard t...
Source: Thrombosis Research - September 25, 2014 Category: Hematology Authors: Yuji Ishibashi, Takanori Matsui, Sho-ichi Yamagishi Tags: Letter to the Editor-in-Chief Source Type: research
Dose Specific Effectiveness and Safety of DOACs in Patients with Non-valvular Atrial Fibrillation: a Canadian Retrospective Cohort Study
Direct oral anticoagulants (DOACs) have been proven to be effective and safe for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, suboptimal adherence, variable dosing and use in patient populations that otherwise would have been excluded from clinical trials may impact the efficacy and safety profile of DOACs in a routine care setting. We compared stroke, bleeding, and mortality rates on and off therapy for standard and low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort.
Source: Thrombosis Research - May 10, 2021 Category: Hematology Authors: Elham Rahme, Richard Godin, Hacene Nedjar, Kaberi Dasgupta, Vicky Tagalakis Source Type: research
Mechanical heart valve prosthesis and warfarin – Treatment quality and prognosis
Conclusion: Patients with a lower warfarin treatment quality measured by TTR have a higher risk of complications such as severe bleeding or death. A TTR of 83% or higher at the individual level should be obtained for best outcome.
Source: Thrombosis Research - March 18, 2014 Category: Hematology Authors: Bartosz Grzymala-Lubanski, Ashkan Labaf, Erling Englund, Peter J. Svensson, Anders Själander Tags: Clinical Studies Source Type: research
Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
Source: Thrombosis Research - May 26, 2014 Category: Hematology Authors: Tereza Lanitis, Thitima Kongnakorn, Lena Jacobson, Anna De Geer Source Type: research
Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis
: Atrial fibrillation (AF) is known as one of the independent risk factors for stroke and might significantly increase its risk. Nowadays, direct-acting oral anticoagulants (DOACs) have been developed and demonstrated a more promising option to warfarin, the conclusion for safety is heterogeneous in different studies. It indicates the importance of comprehensive comparison of safety between DOACs and warfarin.
Source: Thrombosis Research - April 10, 2015 Category: Hematology Authors: Fen Rong, Bin Jia, Pinxian Huang, Henry S. Lynn, Wei Zhang Tags: Regular Article Source Type: research
Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation
Multiple antithrombotic agents are available for stroke prevention in atrial fibrillation (AF). A decision aid can assist patients in making informed decisions that best serves their needs.Objective.To validate a decision aid to assist patients in choosing between antithrombotic agents (antiplatelets, warfarin, direct-acting oral anticoagulants (DOACs)) for AF.
Source: Thrombosis Research - June 14, 2016 Category: Hematology Authors: Safoora Fatima, Anne Holbrook, Sam Schulman, Steve Park, Sue Troyan, Greg Curnew Source Type: research
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial
The ROCKET AF study evaluated once-daily rivaroxaban versus dose-adjusted warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). In this analysis, we compared rivaroxaban with warfarin in patients with AF from China, East Asia, and the rest of the world (ROW).
Source: Thrombosis Research - April 13, 2017 Category: Hematology Authors: Yihong Sun, Dayi Hu, Susanna Stevens, Yuliya Lokhnygina, Richard C. Becker, Scott D. Berkowitz, G ünter Breithardt, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan P. Piccini, Daniel E. Singer, K Tags: Full Length Article Source Type: research
